Surmodics (SRDX) has entered into a definitive agreement to be acquired by GTCR, a private equity firm with investment expertise across healthcare and healthcare technology. The affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive $43.00 per share in cash, for a total equity valuation of approximately $627 million.
Surmodics' Board has unanimously approved the transaction and resolved to recommend that stockholders vote in favor of the transaction. Upon completion, Surmodics will be a privately held company and its common stock will no longer be listed on The Nasdaq Stock Exchange.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.